FTSE MIB
27.113,95 +92,91 (+0,34%) Dow Jones
33.274,15 +415,12 (+1,26%) Nasdaq
12.221,91 +208,43 (+1,74%) Nikkei 225
28.041,48 +258,55 (+0,93%) Petrolio
75,70 +1,33 (+1,79%) Bitcoin EUR
26.173,89 -116,44 (-0,44%)
UCB SA (0NZT.IL)
| Chiusura precedente | 83,68 |
| Aperto | 83,34 |
| Denaro | 76,14 x 0 |
| Lettera | 84,14 x 0 |
| Min-Max giorno | 82,50 - 83,78 |
| Intervallo di 52 settimane | 66,64 - 116,00 |
| Volume | |
| Media Volume | 135.028 |
| Capitalizzazione | 15,721B |
| Beta (5 anni mensile) | 0,32 |
| Rapporto PE (ttm) | 38,96 |
| EPS (ttm) | 2,12 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 1,33 (1,59%) |
| Data ex dividendo | 28 apr 2023 |
| Stima target 1A | N/D |
- GlobeNewswire
UCB Convening Notice to the General Meeting of theShareholders 2023
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the general meeting of shareholders (the “General Meeting”) which will be held on Thursday, 27 April 2023, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notice. Sharehold
- GlobeNewswire
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. “We are excited to partner with UCB, a global leader in epilepsy drug development, as we work together toward a n
